Kirsten Jensen

Kirsten Jensen

Auto-generated profile, based on publicly available information

Kirsten Jensen

Department of Infectious Disease, Imperial College London

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Journal of Infection
Verified
Journal Article
Open access
HLHelen Lai
Helen Lai
MKMagdalena Kolanko
Magdalena Kolanko
LLLucia M. Li
Lucia M. Li
MPMegan E. Parkinson
Megan E. Parkinson
NBNiall J. Bourke
Niall J. Bourke
ESEyal Soreq
Eyal Soreq
Urinary tract infections (UTIs) frequently cause hospitalisation and death in people living with dementia (PLWD). We examine UTI incidence and associated mortality among PLWD relative to matched controls and people with diabetes and investigate whether delayed or withheld treatment further impacts mortality. Data were extracted for n=2,449,814 people aged ≥ 50 in Wales from 2000-2021, with groups matched by age, sex, and multimorbidity. Poisson regression was used to estimate incidences of UTI and mortality. Cox regression was used to study the effects of treatment timing. UTIs in dementia (HR=2.18, 95%CI [1.88-2.53], p<.0) and diabetes (1.21[1.01-1.45], p=.035) were associated with high mortality, with the highest risk in individuals with diabetes and dementia (both) (2.83[2.40-3.34], p<.0) compared to matched individuals with neither dementia nor diabetes. 5.4% of untreated PLWD died within 60 days of GP diagnosis-increasing to 5.9% in PLWD with diabetes. Incidences of UTI and associated mortality are high in PLWD, especially in those with diabetes and dementia. Delayed treatment for UTI is further associated with high mortality.

6 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MCMichael A. Crone
Michael A. Crone
MPMiles Priestman
Miles Priestman
MCMarta Ciechonska
Marta Ciechonska
KJKirsten Jensen
Kirsten Jensen
DSDavid Sharp
David Sharp
PFPaul Freemont
Paul Freemont
The SARS-CoV-2 pandemic has shown how the rapid rise in demand for patient and community sample testing, required for tracing and containing a highly infectious disease, has quickly overwhelmed testing capability globally. With most diagnostic infrastructure dependent on specialised instruments, their exclusive reagent supplies quickly become bottlenecks in times of peak demand, creating an urgent need for novel approaches to boost testing capacity. We address this challenge by refocusing the full synthetic biology stack available at the London Biofoundry onto the development of alternative patient sample testing pipelines. We present a reagent-agnostic automated SARS-CoV-2 testing platform that can be quickly deployed and scaled, and that accepts a diverse range of reagents. Using an in-house-generated, open-source, MS2-virus-like-particle-SARS-CoV-2 standard, we validate RNA extraction and RT-qPCR workflows as well as two novel detection assays based on CRISPR-Cas and Loop-mediated isothermal Amplification (LAMP) approaches. In collaboration with an NHS diagnostic testing lab, we report the performance of the overall workflow and benchmark SARS-CoV-2 detection in patient samples via RT-qPCR, CRISPR-Cas, and LAMP against clinical test sets. The validated RNA extraction and RT-qPCR platform has been installed in NHS diagnostic labs and now contributes to increased patient sample processing in the UK while we continue to refine and develop novel high-throughput diagnostic methods. Finally, our workflows and protocols can be quickly implemented and adapted by members of the Global Biofoundry Alliance and the wider scientific and medical diagnostics community.

11 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
RJRaphaella Jackson
Raphaella Jackson
RCRory Cave
Rory Cave
MTMartin Tran
Martin Tran
KJKirsten Jensen
Kirsten Jensen
MCMichael A. Crone
Michael A. Crone
PFPaul S. Freemont
Paul S. Freemont
Background Urinary tract infections (UTIs) are a leading cause of hospitalization in people living with dementia, making accurate detection and prompt treatment critical in this vulnerable population. Methods This retrospective, longitudinal cohort study evaluated the diagnostic accuracy of self-reported symptoms and urine dipstick test results for identifying UTIs in people with dementia. Participants included 78 community-dwelling individuals over the age of 50 with a confirmed dementia diagnosis. These participants were recruited from cohorts established by the Surrey and Borders Partnership NHS Foundation Trust and the Hammersmith & Fulham Partnership Primary Care Network between late 2019 and 2023. Results The frequency of UTIs in people living with dementia (PLWD) is highly variable, some individuals having nearly chronic infections and others not acquiring a single UTI during their enrolment in the study. The taxonomy of the microbes associated with the urinary tract infections in this cohort were consistent with those that have been observed in other demographics. When we modelled the relationship between self-reported symptoms, dipstick results, and the presence of UTIs we found that there was no significant relationship between UTI and symptoms. However, there was a highly significant correlation between dipstick test results positive for leucocytes and nitrites with the presence of a UTI. Conclusions Urine dipstick tests for nitrites and leucocytes should be incorporated into diagnostic protocols and should also be considered for ongoing surveillance of UTIs in people living with dementia. Study Registration Numbers Research Ethics Committee (REC) reference: 19/LO/0102 Integrated Research Application System (IRAS) project ID: 257561